Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Inclusion Criteria: * Histologic or cytologic diagnosis of NSCLC * Recurrent or metastatic disease that is not amenable to curative therapyMeasurable disease according to RECIST * At least one prior platinum containing regimen for either locally advanced or metastatic disease * Prior chemotherapy must be completed at least 21 days prior to being registered for protocol therapy and the subject must have recovered from the acute toxicity effects of the regimen * Ability and willingness to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period * Prior radiation therapy allowed to \< 25% of the bone marrow * Negative pregnancy test Exclusion Criteria: * No active infection that in the opinion of the investigator would compromise the subject's ability to tolerate therapy. * No serious concomitant systemic disorders that would compromise the safety of the subject or compromise the subject's ability to complete the study, at the discretion of the investigator. * No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for at least 2 years. * No major thoracic or abdominal surgery within 30 days prior to being registered for protocol therapy. * No current breastfeeding